Furthermore, vildagliptin significantly reduced DPP-4 activity mainly by decreasing Oscillibacter and increasing Lactobacillus (95), which provided new therapeutic uses of DPP-4 inhibition to tackle gut microbiome dysfunctions in T2DM. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.